Home › Products › Oncology › Rybrevant 350mg Injection
Rybrevant 350mg Injection
Salt Composition: AMIVANTAMAB
- Manufacturer: JOHNSON & JOHNSON PVT LTD
- Pack Size: 1 VIAL(s)
- Dosage Form: INJECTION
- Strength: 350MG
- Prescription Required
- Cold Chain
- Prepaid Only. Non-Returnable.
- Storage: Store Rybrevant 350mg injection in the refrigerator (2°C to 8°C) Do not freeze keep the injection away from the reach of children and pets. If you have missed any dosing appointments, inform your doctor and schedule immediately.
₹76786.00₹85075.89
Inclusive of all taxes
Product Introduction
Rybrevant 350mg injection contains amivantamab, an antineoplastic agent belonging to the class of bispecific antibodies. It is indicated for the treatment of non-small cell lung cancer (NSCLC) that has metastasised to other parts of the body and harbours specific EGFR gene alterations. It is also used in patients whose disease is unresectable and has progressed during or after treatment with other anticancer medications.
Do not take this injection if you are allergic to amivantamab or any other ingredients in this medicine. Inform your physician if you have a history of lung inflammation or other lung conditions before starting therapy. Report to your physician if you experience symptoms of sudden difficulty in breathing, cough, or fever that may indicate lung inflammation.
Rybrevant 350mg injection is not recommended for children and young people below 18 years of age. Inform your physician if you have kidney, liver, or lung problems before initiating therapy.
The common side effects of Rybrevant 350mg injection include rash, nail inflammation, musculoskeletal pain, shortness of breath, nausea, fatigue, swelling, inflamed and sore mouth, cough, constipation, and vomiting. This medicine may harm the fetus; effective contraception should be used during treatment.
Uses
Non-small cell lung cancer (NSCLC)
How it works
Rybrevant 350mg injection is an epidermal growth factor receptor (EGFR), and mesenchymal-epithelial transition factor (MET) targeted bispecific antibody that has been designed to recognize and attach to specific targets in the body. It targets two proteins found in cancer cells. It works by attaching to these proteins and may help to slow or stop your lung cancer from growing. It may also reduce the size of the tumor.
How to Use
It will be given to you by a doctor or nurse in a hospital or clinic setting trained in cancer chemotherapy. It is given as an intravenous infusion drip (into your vein) for several hours. Do not self-administer the injection. Your doctor will decide the dose and duration of the treatment based on your disease severity, body weight, and other factors.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Common Swelling in the face, hands, and feet Inflammation in the nails Constipation Nausea, vomiting Inflamed and sore mouth Musculoskeletal pain Cough Shortness of breath Tiredness Serious Severe rashes in the skin Eye pain and infection Inflammation of the lungs Infusion reactions
Expert Tips
To reduce skin problems, limit sun exposure during and for 2 months after treatment, wear protective clothing, and apply sunscreen and moisturizers that are alcohol-free regularly on your skin and nails while taking this medicine. Contact your doctor or nurse immediately if you have eye pain or vision problems. Consult your doctor before using contact lenses when you are taking this medicine. Do not breastfeed during the treatment and for 3 months after the last dose. Your doctor may advise you to take certain tests to check for the effectiveness of the therapy.
References
- Rybrevant (amivantamab) 50mg/mL concentrate for solution for infusion - Patient Information Leaflet (PIL) - (emc). www.medicines.org.uk. [revised on 2021] [cited 2023 Apr 6]. Available from: https://www.medicines.org.uk/emc/product/13084/pil
- HIGHLIGHTS OF PRESCRIBING INFORMATION - amivantamab. [revised on 2021] [cited 2023 Apr 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf
- Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR Exon 20 InsertionâMutated NonâSmall-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results from the CHRYSALIS Phase I Study. Journal of Clinical Oncology [revised on 2021 Aug 2] [cited 2023 Apr 6];39(30):JCO.21.00662. Available from: https://pubmed.ncbi.nlm.nih.gov/34339292/
Safety Advice
Pregnancy: unsafe Rybrevant 350mg injection is unsafe to administer in pregnant women because it may affect the fetus. Inform your physician if you are pregnant, suspect pregnancy, or planning to become pregnant. Using an effective birth control method during the treatment and for 3 months after your last dose is necessary.
Lungs: Consult your doctor It is unknown whether Rybrevant 350mg injection can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
Breastfeeding: unsafe Breastfeeding is not recommended in patients taking Rybrevant 350mg injection because the medicine passes into the breast milk in small amounts and may harm your baby.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.